Skip to main content
NVDA+0.10%AAPL-0.10%GOOGL-1.24%MSFT0.00%AMZN+0.25%TSM+1.49%SPCX+1.89%META-0.36%AVGO-0.48%TSLA-0.14%LLY-2.54%BRK-B-0.87%MU+0.09%SKHY+4.05%WMT-1.02%JPM-1.47%AMD+1.74%V-1.55%XOM+2.79%JNJ-1.42%ASMLa-0.87%MA-1.52%ABBV+0.16%CVX+2.88%INTC+1.72%0700.HK+0.94%COST-1.46%1398.HK-1.50%CSCO+1.53%KO-2.76%ORCL+0.49%UNH-1.62%PG-2.76%BAC-1.02%1816.HK+0.44%3988.HK-0.50%HD-2.41%CAT-2.42%0005.HK-1.04%PM-1.13%HSBA.L-1.07%AP2d-0.03%0857.HK-0.93%0939.HK+0.51%AMAT+0.44%GE-2.69%1288.HK-1.94%DELL+0.77%LRCX-0.02%NVS-3.30%USDMXN+0.50%NZDMXN+0.47%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDZAR+0.19%EURCAD+0.18%CADCHF-0.17%EURAUD+0.17%AUDCHF-0.16%USDILS+0.16%AUDNOK-0.15%AUDSGD-0.14%AUDJPY-0.12%USDTRY+0.12%GBPCHF-0.12%CADJPY-0.11%EURGBP+0.10%USDCAD+0.09%AUDNZD-0.09%AUDUSD-0.09%USDCHF-0.09%NZDCHF-0.09%USDDKK-0.08%EURUSD+0.08%NZDCAD+0.08%EURCNH+0.07%GBPAUD+0.07%CHFSGD+0.07%EURNZD+0.07%EURSGD+0.06%CHFJPY+0.06%GBPJPY-0.06%EURJPY+0.06%GBPCAD+0.05%NZDSGD-0.04%NZDJPY-0.04%USDCOP-0.04%USDJPY-0.04%USDSGD-0.03%USDTHB-0.02%EURCHF-0.02%GBPSGD-0.02%USDCNH+0.02%GBPUSD-0.02%USDHKD+0.01%SGDJPY+0.01%NZDUSD-0.01%AUDCAD-0.01%GBPNZD-0.01%GBPZAR0.00%USDSEK0.00%PLNJPY0.00%EURPLN0.00%EURHKD0.00%EURDKK0.00%CHFNOK0.00%USDPLN0.00%EURZAR0.00%NOKJPY0.00%AUDDKK0.00%CHFSEK0.00%EURSEK0.00%EURNOK0.00%EURCZK0.00%USDNOK0.00%USOIL-1.20%XNGUSD-1.03%GAGUSD+0.19%XAGUSD+0.19%XPTUSD+0.16%HG1-0.12%GAUUSD+0.11%XAUUSD+0.11%W10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD-0.84%ETHUSD+22.11%USDTUSD+0.01%XRPUSD+15.55%SOLUSD+15.78%TRXUSDT+0.49%ZECUSDT-0.59%DOGEUSD+20.76%XMRUSDT-4.16%LINKUSD+23.15%BCHUSDT+0.27%XLMUSD-2.00%UNIUSD+1.14%LTCUSD+17.32%SUIUSD-1.89%HBARUSDT-0.49%TONUSD+36.45%TAOUSDT+0.56%AAVEUSD-1.31%DOTUSDT-2.00%ICPUSDT-1.74%ONDOUSDT-0.74%WLDUSDT-3.95%ARBUSDT-0.35%JUPUSDT-2.64%ATOMUSDT+0.23%INJUSDT+1.73%STXUSDT-0.43%TIAUSDT-0.56%PYTHUSDT+5.12%FETUSDT-2.05%SEIUSDT-3.15%IMXUSDT-1.76%GRTUSDT-2.34%OPUSDT-2.61%IOTAUSDT-2.07%WIFUSDT-3.57%POLUSDT-0.74%AXSUSDT-2.33%EOSUSDT-4.65%FARTCOINUSDT-3.06%DYDXUSDT-3.34%GALAUSDT-2.93%ORDIUSDT-2.01%RONINUSDT-1.68%NOTUSDT-2.67%NVDA+0.10%AAPL-0.10%GOOGL-1.24%MSFT0.00%AMZN+0.25%TSM+1.49%SPCX+1.89%META-0.36%AVGO-0.48%TSLA-0.14%LLY-2.54%BRK-B-0.87%MU+0.09%SKHY+4.05%WMT-1.02%JPM-1.47%AMD+1.74%V-1.55%XOM+2.79%JNJ-1.42%ASMLa-0.87%MA-1.52%ABBV+0.16%CVX+2.88%INTC+1.72%0700.HK+0.94%COST-1.46%1398.HK-1.50%CSCO+1.53%KO-2.76%ORCL+0.49%UNH-1.62%PG-2.76%BAC-1.02%1816.HK+0.44%3988.HK-0.50%HD-2.41%CAT-2.42%0005.HK-1.04%PM-1.13%HSBA.L-1.07%AP2d-0.03%0857.HK-0.93%0939.HK+0.51%AMAT+0.44%GE-2.69%1288.HK-1.94%DELL+0.77%LRCX-0.02%NVS-3.30%USDMXN+0.50%NZDMXN+0.47%GBPTRY+0.41%GBPHKD+0.32%GBPMXN-0.28%USDZAR+0.19%EURCAD+0.18%CADCHF-0.17%EURAUD+0.17%AUDCHF-0.16%USDILS+0.16%AUDNOK-0.15%AUDSGD-0.14%AUDJPY-0.12%USDTRY+0.12%GBPCHF-0.12%CADJPY-0.11%EURGBP+0.10%USDCAD+0.09%AUDNZD-0.09%AUDUSD-0.09%USDCHF-0.09%NZDCHF-0.09%USDDKK-0.08%EURUSD+0.08%NZDCAD+0.08%EURCNH+0.07%GBPAUD+0.07%CHFSGD+0.07%EURNZD+0.07%EURSGD+0.06%CHFJPY+0.06%GBPJPY-0.06%EURJPY+0.06%GBPCAD+0.05%NZDSGD-0.04%NZDJPY-0.04%USDCOP-0.04%USDJPY-0.04%USDSGD-0.03%USDTHB-0.02%EURCHF-0.02%GBPSGD-0.02%USDCNH+0.02%GBPUSD-0.02%USDHKD+0.01%SGDJPY+0.01%NZDUSD-0.01%AUDCAD-0.01%GBPNZD-0.01%GBPZAR0.00%USDSEK0.00%PLNJPY0.00%EURPLN0.00%EURHKD0.00%EURDKK0.00%CHFNOK0.00%USDPLN0.00%EURZAR0.00%NOKJPY0.00%AUDDKK0.00%CHFSEK0.00%EURSEK0.00%EURNOK0.00%EURCZK0.00%USDNOK0.00%USOIL-1.20%XNGUSD-1.03%GAGUSD+0.19%XAGUSD+0.19%XPTUSD+0.16%HG1-0.12%GAUUSD+0.11%XAUUSD+0.11%W10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD-0.84%ETHUSD+22.11%USDTUSD+0.01%XRPUSD+15.55%SOLUSD+15.78%TRXUSDT+0.49%ZECUSDT-0.59%DOGEUSD+20.76%XMRUSDT-4.16%LINKUSD+23.15%BCHUSDT+0.27%XLMUSD-2.00%UNIUSD+1.14%LTCUSD+17.32%SUIUSD-1.89%HBARUSDT-0.49%TONUSD+36.45%TAOUSDT+0.56%AAVEUSD-1.31%DOTUSDT-2.00%ICPUSDT-1.74%ONDOUSDT-0.74%WLDUSDT-3.95%ARBUSDT-0.35%JUPUSDT-2.64%ATOMUSDT+0.23%INJUSDT+1.73%STXUSDT-0.43%TIAUSDT-0.56%PYTHUSDT+5.12%FETUSDT-2.05%SEIUSDT-3.15%IMXUSDT-1.76%GRTUSDT-2.34%OPUSDT-2.61%IOTAUSDT-2.07%WIFUSDT-3.57%POLUSDT-0.74%AXSUSDT-2.33%EOSUSDT-4.65%FARTCOINUSDT-3.06%DYDXUSDT-3.34%GALAUSDT-2.93%ORDIUSDT-2.01%RONINUSDT-1.68%NOTUSDT-2.67%
MP

Mirum Pharmaceuticals, Inc. (MIRM)

NASDAQ • Healthcare

$80.39
-$2.7 (-3.3%)
Market closed

Last close at October 23, 2026 at 20:00 UTC

Open$82.39
Day Range$80.24 - $83
Avg. Volume (3M)822.9K
Market Cap$5.2B
52 Week Range
$63.23$130
Next EarningsIn 9 daysNov 3, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$176.2M100%
Gross Profitminus cost of goods$145.8M83%

In plain terms: out of every $100 in revenue, Mirum Pharmaceuticals, Inc. currently loses $38.

Fundamentals & Financials

Revenue (TTM)
$618M
Net Income (TTM)
-$860.2M
EPS (TTM)
-$14.56
ROA (TTM)
-82.32%
Current Ratio
2.86

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-650.0%Q1 2026-$0.11
-3257.5%Q2 2026-$13.43
-42.8%Q3 2026-$1.06
Next

Nov 3

in 9 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -42.8%

Mirum Pharmaceuticals’ revenue topped consensus in the second fiscal quarter of 2026, based on preliminary results reported August 5, 2026, with revenue of $176.2 million against a $166.3 million estimate (+6%, topped). Revenue rose ~38% to roughly $176 million from about $128 million a year ago, reflecting continued demand for its LIVMARLI franchise in rare cholestatic liver diseases. Profitability remained high, with gross profit of about $145.9 million translating to a gross margin of ~83%. Consensus for the next period calls for EPS of -$0.53 on revenue of $178.1 million.

Next report — what to expect

Mirum Pharmaceuticals, Inc. (MIRM) reports on November 3, 2026. Wall Street is looking for EPS of -$0.53 on revenue of $178.1 million. For trailing context, revenue grew +37.9% year over year last quarter. Mirum has beaten EPS in 4 of 8 most recent quarters.

View full earnings history

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. develops and commercializes therapies for serious rare and orphan diseases as a biotechnology company listed on NASDAQ under MIRM. The business generated $521.3 million in FY2025 revenue, centered on liver-disease treatments and a pipeline aimed at several cholestatic conditions.

Name
Mirum Pharmaceuticals, Inc.
CEO
Christopher Peetz
Website
www.mirumpharma.com
Industry
Healthcare
Year Founded
2018
Employees
433

Today's Snapshot

AI-generated

The day ended with MIRM 3.3% lower at 80.39, in line with a weaker sector. Mirum Pharmaceuticals reported success in a Phase 3 trial. MIRM reports earnings on 3 November.

Trading Volume

Above 10d avg 692.5K

788.2K

vs S&P 500 Today

Underperforming Market

-2.74%

Updated: October 23, 2026 at 20:22 UTC

Technical Indicators

0 Buy3 Neutral5 Sell
MIRM is rated Strong Sell as the chart shows clear downside alignment across trend and price metrics. Price sits well below short-, medium- and 200-day moving averages, and ADX indicates a pronounced directional trend to the downside while momentum measures and MACD are negative, reinforcing selling pressure. Volatility is elevated relative to recent levels, yet on-balance volume is anomalously positive, suggesting mixed participation but insufficient to counter the price bias. The classic pivot lies above the current price, adding resistance near recent levels. Technical takeaway: Strong Sell — downward trend and negative momentum dominate.
All signals
  • EMA (5 indicators)$82.52 - $94.63
    Sell
  • RSI (14)39.32
    Neutral
  • Stochastic %K (14, 3, 3)43.02
    Neutral
  • MACD Level (12, 26)-2.77
    Neutral

Peers & Related Assets

MDGLMadrigal Pharmaceuticals, Inc.
$434.24-4.2%
TVTXTravere Therapeutics, Inc.
$50.08-4.5%
AGIOAgios Pharmaceuticals, Inc.
$37-0.5%
RAREUltragenyx Pharmaceutical Inc.
$15.65-1.9%
ALTAltimmune, Inc.
$2.12-2.3%
ENTAEnanta Pharmaceuticals, Inc.
$11.64+0.2%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.